SG10201804305SA - Stabilized ophthalmic galactomannan formulations - Google Patents
Stabilized ophthalmic galactomannan formulationsInfo
- Publication number
- SG10201804305SA SG10201804305SA SG10201804305SA SG10201804305SA SG10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- stabilized ophthalmic
- stabilized
- ophthalmic
- guar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Stabilized Ophthalmic Galactomannan Formulations The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise 5 galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride. 10 (No suitable figure)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33151110P | 2010-05-05 | 2010-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201804305SA true SG10201804305SA (en) | 2018-06-28 |
Family
ID=44626461
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012081386A SG185422A1 (en) | 2010-05-05 | 2011-05-04 | Stabilized ophthalmic galactomannan formulations |
SG10201804305SA SG10201804305SA (en) | 2010-05-05 | 2011-05-04 | Stabilized ophthalmic galactomannan formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012081386A SG185422A1 (en) | 2010-05-05 | 2011-05-04 | Stabilized ophthalmic galactomannan formulations |
Country Status (16)
Country | Link |
---|---|
US (2) | US20110275593A1 (en) |
EP (1) | EP2566447B1 (en) |
JP (1) | JP5794744B2 (en) |
KR (2) | KR20130060228A (en) |
CN (2) | CN102939074A (en) |
AR (1) | AR081015A1 (en) |
AU (1) | AU2011248129B2 (en) |
BR (1) | BR112012028308B1 (en) |
CA (1) | CA2798069C (en) |
ES (1) | ES2809304T3 (en) |
MX (1) | MX2012012826A (en) |
NZ (1) | NZ603345A (en) |
SG (2) | SG185422A1 (en) |
TW (1) | TWI606841B (en) |
WO (1) | WO2011140203A2 (en) |
ZA (1) | ZA201208199B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101592872B1 (en) * | 2008-04-26 | 2016-02-12 | 알콘 리서치, 리미티드 | Polymeric artificial tear system |
TWI492769B (en) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | Injectable aqueous ophthalmic composition and method of use therefor |
TW201336527A (en) * | 2012-02-10 | 2013-09-16 | Alcon Res Ltd | Aqueous pharmaceutical composition with enhanced stability |
UA113434C2 (en) * | 2012-05-04 | 2017-01-25 | Алкон Рісерч, Лтд. | Ophthalmic compositions with improved dessication protection and retention |
AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
JP7057290B2 (en) | 2016-06-27 | 2022-04-19 | アキリオン ファーマシューティカルズ,インコーポレーテッド | Quinazoline and indole compounds for the treatment of medical disorders |
US11260035B2 (en) | 2016-10-12 | 2022-03-01 | Ps Therapies Ltd | Topical compositions and methods of use thereof |
WO2018071619A1 (en) * | 2016-10-12 | 2018-04-19 | Ps Therapies Ltd | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
US11583496B2 (en) | 2016-10-12 | 2023-02-21 | PS Therapy Inc. | Drug vehicle compositions and methods of use thereof |
CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
EP3841086A4 (en) | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
WO2020081723A1 (en) | 2018-10-16 | 2020-04-23 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
TWI757773B (en) * | 2019-06-28 | 2022-03-11 | 瑞士商愛爾康公司 | Ophthalmic compositions |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8028A (en) * | 1851-04-08 | Hokse-poweb | ||
US4136173A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
DE3827561C1 (en) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
US5505953A (en) * | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
EP0999825B1 (en) * | 1997-07-29 | 2003-10-01 | Alcon Laboratories, Inc. | Ophthalmic compositions containing galactomannan polymers and borate |
GB9808461D0 (en) * | 1998-04-22 | 1998-06-17 | Innovative Tech Ltd | Solid borate-diol interaction products |
US7084130B2 (en) * | 2001-12-11 | 2006-08-01 | Alcon, Inc. | Intraocular irrigating solution having improved flow characteristics |
TWI336257B (en) * | 2003-06-13 | 2011-01-21 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
US20100021561A1 (en) * | 2006-09-21 | 2010-01-28 | Chowhan Masood A | Self-preserved aqueous pharmaceutical compositions |
TWI434926B (en) | 2006-12-11 | 2014-04-21 | Alcon Res Ltd | Use of peo-pbo block copolymers in ophthalmic compositions |
AR066901A1 (en) * | 2007-05-18 | 2009-09-23 | Alcon Mfg Ltd | PHODFOLIPID COMPOSITIONS FOR THE CLOSURE OF CONTACT LENSES AND PRESERVATION OF PHARMACEUTICAL COMPOSITIONS |
KR101592872B1 (en) * | 2008-04-26 | 2016-02-12 | 알콘 리서치, 리미티드 | Polymeric artificial tear system |
MX2011007714A (en) | 2009-02-05 | 2011-12-06 | Alcon Res Ltd | Process for purifying guar. |
-
2011
- 2011-05-04 EP EP11720357.0A patent/EP2566447B1/en active Active
- 2011-05-04 NZ NZ603345A patent/NZ603345A/en not_active IP Right Cessation
- 2011-05-04 WO PCT/US2011/035165 patent/WO2011140203A2/en active Application Filing
- 2011-05-04 AU AU2011248129A patent/AU2011248129B2/en active Active
- 2011-05-04 BR BR112012028308-1A patent/BR112012028308B1/en active IP Right Grant
- 2011-05-04 JP JP2013509217A patent/JP5794744B2/en active Active
- 2011-05-04 CA CA2798069A patent/CA2798069C/en active Active
- 2011-05-04 US US13/100,439 patent/US20110275593A1/en not_active Abandoned
- 2011-05-04 KR KR1020127031590A patent/KR20130060228A/en active Application Filing
- 2011-05-04 TW TW100115587A patent/TWI606841B/en active
- 2011-05-04 CN CN2011800292803A patent/CN102939074A/en active Pending
- 2011-05-04 ES ES11720357T patent/ES2809304T3/en active Active
- 2011-05-04 SG SG2012081386A patent/SG185422A1/en unknown
- 2011-05-04 CN CN201610986410.7A patent/CN106389325A/en active Pending
- 2011-05-04 SG SG10201804305SA patent/SG10201804305SA/en unknown
- 2011-05-04 KR KR1020177037138A patent/KR20180001587A/en not_active Application Discontinuation
- 2011-05-04 MX MX2012012826A patent/MX2012012826A/en active IP Right Grant
- 2011-05-05 AR ARP110101556A patent/AR081015A1/en unknown
-
2012
- 2012-10-31 ZA ZA2012/08199A patent/ZA201208199B/en unknown
-
2013
- 2013-05-13 US US13/892,429 patent/US8846641B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AR081015A1 (en) | 2012-05-30 |
US8846641B2 (en) | 2014-09-30 |
ZA201208199B (en) | 2014-01-29 |
NZ603345A (en) | 2014-12-24 |
TWI606841B (en) | 2017-12-01 |
CA2798069A1 (en) | 2011-11-10 |
JP5794744B2 (en) | 2015-10-14 |
BR112012028308B1 (en) | 2021-09-28 |
CN102939074A (en) | 2013-02-20 |
KR20130060228A (en) | 2013-06-07 |
KR20180001587A (en) | 2018-01-04 |
AU2011248129B2 (en) | 2014-10-09 |
WO2011140203A3 (en) | 2012-04-19 |
BR112012028308A2 (en) | 2016-11-01 |
SG185422A1 (en) | 2012-12-28 |
US20110275593A1 (en) | 2011-11-10 |
EP2566447A2 (en) | 2013-03-13 |
EP2566447B1 (en) | 2020-07-15 |
AU2011248129A1 (en) | 2012-11-29 |
MX2012012826A (en) | 2013-01-28 |
CN106389325A (en) | 2017-02-15 |
ES2809304T3 (en) | 2021-03-03 |
TW201141524A (en) | 2011-12-01 |
CA2798069C (en) | 2016-07-05 |
US20130244971A1 (en) | 2013-09-19 |
WO2011140203A2 (en) | 2011-11-10 |
JP2013525493A (en) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201804305SA (en) | Stabilized ophthalmic galactomannan formulations | |
AR112286A2 (en) | POLYMERIC SYSTEM OF ARTIFICIAL TEARS | |
MX2014009757A (en) | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
MX2013002422A (en) | Salts of lorcaserin with optically active acids. | |
MX2013001677A (en) | Stable formulations of linaclotide. | |
PH12014502571A1 (en) | Ophthalmic compositions with improved dessication protection and retention | |
IN2012DN02177A (en) | ||
IN2012DN02730A (en) | ||
IN2012DN00754A (en) | ||
GB201106743D0 (en) | Novel compounds | |
MX344473B (en) | Semisolid aqueous pharmaceutical composition containing tapentadol. | |
TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
MX345404B (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-m ethylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate. | |
MY162175A (en) | Aqueous drug delivery system | |
TN2012000261A1 (en) | Aerosol formulation for copd | |
TW200718698A (en) | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | |
EA201591188A1 (en) | DELIVERY OF GLETIRAMER ACETATE THROUGH THE SLIGHTY SHELL | |
MX2012006265A (en) | Hypersulfated disaccharide formulations. | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
WO2011076840A3 (en) | Aerosol formulation for copd | |
MX2015007794A (en) | Oral transmucosal delivery of glatiramer acetate. | |
MX2014004210A (en) | 2-oxo-piperidinyl derivatives. | |
BR112012020828A2 (en) | pharmaceutical preparation containing miramistin | |
MX2012012978A (en) | Method of producing pleurodesis. | |
EP2780009A4 (en) | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |